Medopad raises $25M led by Bayer to develop biomarkers tracked via apps and wearables

Medopad, the UK startup that has been working with Tencent to develop AI-based methods for building and tracking “digital” biomarkers — measurable indicators of the progression of illnesses and diseases that are picked up not with blood samples or in-doctor visits but using apps and wearables, has announced another round of funding to expand the scope of its developments.

It has picked up $25 million led by pharmaceuticals giant Bayer, which will be working together with Medopad to build digital biomarkers and therapeutics related to heart health.

While Medopad also tracks biomarkers, it’s taking a very different, non-invasive route to building its solutions.

The company constructs its algorithms and tracking working with pharmaceutical and tech partners to build the solution end-to-end, leaning on advances in software and hardware to fulfil ideas that have been unattainable goals for a long time.

In recent times, however, with the advent of advanced computer vision and far better sensors on devices, a new category of digital biomarkers, as Vahdat calls them, are being created — for example, by tracking how a person is walking — her/his gait and other metrics — to provide similar guidance to a clinician on the patient’s progress.

Vahdat said that all patient data is only collected with consent, and if any data from Medopad is passed to its partners, it’s anonymised.

Full Article